Who decides whether a product is a drug or a device

The category decides the rulebook

Whether something is regulated as a drug or as a device is not a labeling preference. It changes the review pathway, the manufacturing rules, the reporting duties and the evidence required before sale.

Part 3 of title 21 is headed Product Jurisdiction, and its job is to assign that question to an answer.

It works at the level of the FDA's own structure. An agency component means one of the centers that reviews biologics, devices or drugs, or an alternative organizational component.

The person who makes the call has a title in the regulation: the product jurisdiction officer. That is defined as the person or persons "responsible for designating the component of FDA with primary jurisdiction for the premarket review and regulation of a combination product."

What counts as a combination product

Section 3.2(e) sets out four shapes, and the range is wider than most summaries suggest.

The first is a single object. It is "A product comprised of two or more regulated components, i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise combined or mixed and produced as a single entity."

The second is a box: "Two or more separate products packaged together in a single package or as a unit."

The third is the one that surprises people, because nothing is packaged together at all. It covers a product "packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product." Two conditions follow: "both are required to achieve the intended use," and approving the new one would require changing the other's labeling.

The fourth applies the same logic to two investigational products intended for use only with each other.

The single question the assignment turns on

Section 3.4 states the test in one line. To designate the reviewing component, "the agency shall determine the primary mode of action of the product."

Mode of action is defined as "the means by which a product achieves an intended therapeutic effect or action." Therapeutic is defined broadly, covering any effect intended to "diagnose, cure, mitigate, treat, or prevent disease, or affect the structure or any function of the body."

Primary mode of action is narrower and is where the decision lands. It is "the single mode of action of a combination product that provides the most important therapeutic action." The most important action is the one "expected to make the greatest contribution to the overall intended therapeutic effects."

The assignment then follows mechanically. A drug primary mode goes to the drug center, a device primary mode to the device center, a biological product primary mode to the biologics center.

The regulation also acknowledges the obvious: because a combination product is more than one kind of regulated article, such products "will typically have more than one identifiable mode of action."

What happens when the question has no clean answer

Paragraph (b) of section 3.4 handles the tie, and it does not resort to a coin toss.

It applies where "it is not possible to determine, with reasonable certainty, which one mode of action will provide a greater contribution than any other."

The first fallback is precedent. The agency assigns the product "to the agency component that regulates other combination products that present similar questions of safety and effectiveness with regard to the combination product as a whole."

The second fallback is expertise. Where no such precedent exists, the product goes "to the agency component with the most expertise related to the most significant safety and effectiveness questions presented."

And a designation is not a wall. Paragraph (c) confirms that naming one component does not preclude consultations with others, or a requirement of separate applications in appropriate cases.

Asking first, in fifteen pages

Section 3.7 is the route a sponsor takes when the answer is unclear, and its constraints are specific.

It is for the sponsor of a product not covered by an intercenter agreement, or one where the reviewing component "is unclear or in dispute."

The timing is before, not after. A sponsor "should file a request for designation before filing any application for premarket review," and is encouraged to file "as soon as there is sufficient information for the agency to make a determination."

The length is capped. The request "must not exceed 15 pages, including attachments."

Inside those pages the regulation asks for a full picture. It wants the product's chemical, physical or biological composition, the manufacturing processes "including the sources of all components," the proposed indications, the dose and route, and results of developmental work.

The heart of it is one item. The sponsor must give a "Description of all known modes of action," identify "the single mode of action that provides the most important therapeutic action of the product," and state "the basis for that determination."

The sixty-day rule that goes the sponsor's way

Section 3.8 sets the response, and it contains a default most readers will not expect.

A request is reviewed for completeness within five working days. Then, "Within 60 days of the filing date of a request for designation, the product jurisdiction officer will issue a letter of designation."

The consequence of missing that deadline is stated in the same paragraph. If no letter issues within 60 days, "the sponsor's recommendation of the center with primary jurisdiction, in accordance with § 3.7(c)(3), shall become the designated agency component."

A sponsor who disagrees with a letter has fifteen days to file a request for reconsideration, capped at five pages, and "No new information may be included." The officer acts on it in writing within fifteen days.

How settled a designation is

Section 3.9 answers that, and the answer is: quite settled, with a defined escape.

A letter of designation "constitutes an agency determination that is subject to change only as provided in paragraph (b)."

The officer may change it with the sponsor's written consent, or without consent "to protect the public health or for other compelling reasons."

A nonconsensual change comes with process. The sponsor gets 30 days written notice, may request another 30 days to file written objections capped at fifteen pages, and is granted a timely meeting on request. The officer must then issue a written determination with reasons within 30 days of receiving the objections.

And it takes a signature high up. A nonconsensual change "requires the concurrence of the Principal Associate Commissioner."

Why this is worth knowing in a peptide market

Most compounded peptide products never touch this machinery, because part 3 governs the assignment of premarket review and most of this market has no premarket review to assign.

It is still the right frame for two recurring situations. The first is a delivery system sold with a drug, where the third definition in section 3.2(e) can reach products that are not packaged together at all.

The second is any claim about which FDA center oversees something. That is a determination made in a letter, on a defined timetable, changeable only in defined ways. It is not a description a company supplies about itself.

The intercenter agreements section 3.5 refers to are guidance documents held at the agency rather than text in the Code. They were not read for this page, and nothing here characterizes their contents beyond what section 3.5 itself states about them.

This is a summary of a regulation. It classifies no product, names no seller, and is not legal advice.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 21 Code of Federal Regulations section 3.2, Definitions — Electronic Code of Federal Regulations, Office of the Federal Register, August 2005
2. Title 21 Code of Federal Regulations section 3.4, Designated agency component — Electronic Code of Federal Regulations, Office of the Federal Register, August 2005
3. Title 21 Code of Federal Regulations section 3.5, Procedures for identifying the designated agency component — Electronic Code of Federal Regulations, Office of the Federal Register, July 2023
4. Title 21 Code of Federal Regulations section 3.7, Request for designation — Electronic Code of Federal Regulations, Office of the Federal Register, August 2005
5. Title 21 Code of Federal Regulations section 3.8, Letter of designation — Electronic Code of Federal Regulations, Office of the Federal Register, November 1991
6. Title 21 Code of Federal Regulations section 3.9, Effect of letter of designation — Electronic Code of Federal Regulations, Office of the Federal Register, June 2003